Skip to main content

Professor Michael Loebinger, MA, FRCP, PhD

Professor Michael Loebinger, MA, FRCP, PhD

Director of the Lung Divisiona
Clinical Director of Laboratory Medicinea
Deputy Medical Director
Consultant Respiratory Medicine
Royal Brompton & Harefield Hospitals
Professor of Practice (Respiratory Medicine)
National Heart and Lung Institute
Imperial College London
London, United Kingdom

Related Videos

Professor Loebinger, can you kindly introduce yourself and share with us your role at the Royal Brompton & Harefield Hospitals? And, what you plan to cover in this landmark iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Professor Loebinger, can you kindly introduce yourself and share with us your role at the Royal Brompton & Harefield Hospitals? And, what you plan to cover in this landmark iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Given the outcome gains seen with brensocatib in WILLOW, which positive signals—such as fewer exacerbations, better quality of life, less antibiotic use, and preserved FEV1—were likewise confirmed in the ASPEN trial?

Given the outcome gains seen with brensocatib in WILLOW, which positive signals—such as fewer exacerbations, better quality of life, less antibiotic use, and preserved FEV1—were likewise confirmed in the ASPEN trial?

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

From your perspective as an investigator in the brensocatib trials, what do you feel are the most important translation take-aways about the deployment of this novel neutrophil-and-inflammation-targeting therapy at the front lines of NCFBE care?

From your perspective as an investigator in the brensocatib trials, what do you feel are the most important translation take-aways about the deployment of this novel neutrophil-and-inflammation-targeting therapy at the front lines of NCFBE care?

With respect to targeting therapy at neutrophil-mediated inflammation, how does our understanding of the underlying pathobiology help select among treatment options that frequently require multi-modal approaches?

With respect to targeting therapy at neutrophil-mediated inflammation, how does our understanding of the underlying pathobiology help select among treatment options that frequently require multi-modal approaches?

Can you discuss what systematic approach you apply to confirming the diagnosis of NCFBE?

Can you discuss what systematic approach you apply to confirming the diagnosis of NCFBE?

What are the infectious etiologies that undergird NCFBE and how does documentation of these pathogens affect treatment decisions for this disease state?

What are the infectious etiologies that undergird NCFBE and how does documentation of these pathogens affect treatment decisions for this disease state?

Given that diverse pathogens worsen NCFBE, which additional mechanisms—particularly neutrophil-driven inflammation and unchecked serine protease activity—serve as core forces that fuel airway injury, exacerbations, and ongoing disease progression?

Given that diverse pathogens worsen NCFBE, which additional mechanisms—particularly neutrophil-driven inflammation and unchecked serine protease activity—serve as core forces that fuel airway injury, exacerbations, and ongoing disease progression?